SAN DIEGO, May 24, 2011 /PRNewswire/ — Prometheus Laboratories
Inc., (“Prometheus”) a specialty pharmaceutical and diagnostic
company, today announced that it has entered into a definitive
agreement to be acquired by Nestle Health Science S.A., a
wholly-owned subsidiary of Nestle S.A., for an undisclosed amount.
Nestle Health Science became operational in January 2011 with
the goal of pioneering science-based nutritional solutions in order
to deliver improved personalized healthcare for medical conditions.
In the longer term, the company aims to use nutritional solutions
to change the healthcare paradigm and deliver affordable and
effective health benefits which are also safe and sustainable.
Prometheus’ capabilities strongly support Nestle Health
Science’s ambition of pioneering science-based nutritional
solutions to deliver improved personalized healthcare for medical
conditions.
“This is a strategic move into gastrointestinal diagnostics.
Prometheus’s leading edge diagnostics technology and outstanding
sales force will help us to develop an integrated approach to
personalized healthcare,” said Luis Cantarell, Nestle Health
Science President and Chief Executive Officer. “It is fully
consistent with our vision of pioneering science-based nutritional
solutions to deliver improved personalized healthcare for medical
conditions.”
“We are delighted to join Nestle Health Science, and we share
their commitment to personalized healthcare. With Nestle Health
Science’s support, we will accelerate the development of our
innovative diagnostic platforms for gastroenterology and oncology
and potentially into additional important therapeutic areas,” said
Joseph M. Limber, Prometheus President & Chief Executive
Officer. “We also intend to leverage Nestle Health Science’s
nutritional product offerings and geographic presence to expand our
successful Rx/Dx business model into a Dx/Nx/Rx model.”
Prometheus’s strong expertise a
‘/>”/>
